ClinicalTrials.gg
Active, not recruitingNCT06799000Updated Oct 15, 2026

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

A Phase 3 interventional study of Remibrutinib Dose A and Remibrutinib Dose B in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 139 sites in 20 countries. Open to participants aged 12 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
588
Allocation
Randomized
Ages
12 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.

Enrollment
3rd of 10
588 · median 545
Started
2025
with 6 others
Phase 3
6 of 21
1 open now
Primary completion
2027-05
later than 4 of 13 live
Registered
12th of 21
by date

Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is one of 7 that started in 2025, is one of 6 in phase 3, reaches primary completion later than 4 of the 13 other live ones, and was the 12th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 12 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Hidradenitis Suppurativa by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).

Read the detailed description

The total duration of the study is 76 weeks and consists of: Screening (up to 4 weeks), Treatment Period 1 (16 weeks, double-blind treatment with remibrutinib (Dose A or Dose B) or placebo, Treatment Period 2 (52 weeks, treatment with remibrutinib (Dose A or Dose B) and Safety Follow-Up (treatment-free follow-up for 4 weeks).

Participants who prematurely discontinue study treatment (either during Treatment Period 1 or Treatment Period 2) are encouraged to remain in the study. Participants who do not wish to remain in the study will enter a 4-week Safety Follow-Up period.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Bruton's tyrosine kinase (BTK) inhibitor
  • Hidradenitis Suppurativa
  • HS
  • Hidradenitis Suppurativa clinical response
  • HiSCR
  • remibrutinib
  • LOU064
  • Hidradenitides, Suppurativa
  • Hidradenitis, Suppurativa
  • Suppurativa Hidradenitides
  • Suppurativa Hidradenitis
  • Acne inversa,
  • Verneuil disease
  • Inflammatory skin disease
  • Chronic skin condition
04

Who can participate

Ages eligible
12 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male and female participants ≥ 12 years of age at the time of signing of the .
  2. Diagnosis of HS based on clinical history and physical examination for at least 6 months prior to the Baseline visit.
  3. Participants with moderate to severe HS defined as:

    • A total of at least 5 AN count (abscesses and/or inflammatory nodules) AND
    • Inflammatory lesions should affect at least 2 distinct anatomic areas (e.g., left and right axillae)

Key Exclusion Criteria:

  1. Presence of more than 20 fistulae/tunnels (both draining and non-draining) in total at baseline.
  2. Any active skin disease or conditions that may interfere with the assessment of HS.
  3. Previous exposure to remibrutinib or other BTK inhibitors.
  4. Use of other drugs within 5 half-lives of enrollment, or within 30 days (for small molecules) prior to randomization, or until the pharmacodynamic effect has returned to baseline (for biologics), whichever is longer.
  5. Significant bleeding risk or coagulation disorders.
  6. History of gastrointestinal bleeding.
  7. Requirement for anti- (except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d) or anti-coagulant medication.
  8. History or current hepatic disease.
  9. Evidence of cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the Investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant.
  10. History of to any of the study drug constituents.
  11. Known or suspected infectious disease that is active, chronic or recurrent which precludes the participant from participating in the trial as per investigator's assessment. These infectious diseases include and are not limited to opportunistic infections (e.g., tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis) and/or known or suspected (HIV) infection. Should it be required by local regulations and/or considered appropriate by the investigator, an HIV test can be performed to confirm eligibility.
  12. History of administration within 6 weeks prior to randomization or requirement to receive these vaccinations at any time while on study treatment.
  13. Major surgery within 8 weeks prior to screening or planned surgery for the duration of the study.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
588 participants (actual)

Study arms

  • Experimental
    Remibrutinib Dose A (Treatment Period 1 and 2)

    Participants randomized to receive remibrutinib Dose A during Treatment Period 1 and 2

    Drug: Remibrutinib Dose A

  • Experimental
    Remibrutinib Dose B (Treatment Period 1 and 2)

    Participants randomized to receive remibrutinib Dose B during Treatment Period 1 and 2

    Drug: Remibrutinib Dose B

  • Placebo comparator
    Placebo (Treatment Period 1) + remibrutinib Dose B (Treatment Period 2)

    Participants randomized to receive placebo during Treatment Period 1 followed by remibrutinib dose B during Treatment Period 2

    Drug: Remibrutinib Dose B · Drug: Placebo 1 · Drug: Placebo 2

Interventions

  • Remibrutinib Dose A (oral)

    Also known as: LOU064

  • Remibrutinib Dose B (oral)

    Also known as: LOU064

  • DrugPlacebo 1

    Placebo matching to remibrutinib Dose A (oral)

  • DrugPlacebo 2

    Placebo matching to remibrutinib Dose B (oral)

06

What researchers measure

Primary outcomes

  1. Proportion of participants with Hidradenitis Suppurativa clinical response 50 (HiSCR50) at Week 16

    HiSCR50 is defined as at least a 50% decrease in Abscess and Inflammatory Nodule (AN) count with no increase in the number of abscesses and in the number of draining tunnels/fistulae compared to baseline.

    Time frame: Week 16

Secondary outcomes

  1. Proportion of participants with Abscesses and inflammatory nodules 50 (AN50) response at Week 16

    AN50 is defined as at least a 50% decrease in Abscess and Inflammatory Nodule (AN) count compared to baseline

    Time frame: Week 16

  2. Percentage change from baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) at Week 16

    The IHS4 is a disease severity scoring system developed by the European Hidradenitis Suppurativa Foundation. It is a weighted sum of different types of inflammatory lesion counts, calculated as 1 x number of nodules + 2 x number of abscesses + 4 x number of draining tunnels (=fistulae=sinuses).

    Time frame: From baseline up to Week 16

  3. Proportion of participants with HiSCR75 response at Week 16

    HiSCR75 is defined as at least a 75% decrease in Abscess and Inflammatory Nodule (AN) count with no increase in the number of abscesses and in the number of draining tunnels/fistulae compared to baseline.

    Time frame: Week 16

  4. Proportion of participants experiencing Hidradenitis Suppurativa (HS) flares at Week 16

    Flare is defined as at least a 25% increase in AN count with a minimum increase of 2 AN relative to baseline.

    Time frame: Up to Week 16

  5. Proportion of participants with HiSCR50 response at Week 8

    HiSCR50 is defined as at least a 50% decrease in Abscess and Inflammatory Nodule (AN) count with no increase in the number of abscesses and in the number of draining tunnels/fistulae compared to baseline.

    Time frame: Week 8

  6. Proportion of participants with HiSCR90 response at Week 16

    HiSCR90 is defined as at least a 90% decrease in Abscess and Inflammatory Nodule (AN) count with no increase in the number of abscesses and in the number of draining tunnels/fistulae compared to baseline.

    Time frame: Week 16

  7. Proportion of participants with clinical response in HS related skin pain (NRS 30), at worst at Week 16

    Achievement of NRS30 at Week 16, among participants with baseline NRS ≥ 3 (pooled data from studies CLOU064J12301 and CLOU064J12302). NRS30 is defined as at least a 30% reduction and at least 2-unit reduction from baseline in Patient's Global Assessment of Skin Pain - at worst over the past 7 days.

    Time frame: Week 16

  8. Incidence of treatment emergent adverse events and serious adverse events during the study

    The distribution of adverse events will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.

    Time frame: From randomization to end of study, assessed up to 72 weeks.

07

Study locations

139 sites
  • Medical Dermatology Specialists
    Phoenix, Arizona 85006, United States
  • Johnson Dermatology
    Fort Smith, Arkansas 72916, United States
  • Arkansas Research Trials
    North Little Rock, Arkansas 72117, United States
  • Cheryl Effron MD Inc
    Anaheim, California 92807, United States
  • Physioseq
    Sacramento, California 95826, United States
  • Olive View UCLA Medical Center
    Sylmar, California 91342, United States
  • Clinical Trials Research Institute
    Thousand Oaks, California 91320, United States
  • Howard University College of Medicine
    Washington D.C., District of Columbia 20060, United States
  • Florida Academic Centers Research and Education LLC
    Coral Gables, Florida 33134, United States
  • University of MiamiHealth System
    Miami, Florida 33125, United States
  • Ziaderm Research LLC
    North Miami Beach, Florida 33162, United States
  • Revival Research Institute LLC
    Evans, Georgia 30809, United States
  • Gwinnett Clinical Research Center
    Snellville, Georgia 30078, United States
  • Immunology-Rheumatology Research
    Suwanee, Georgia 30024, United States
  • Illinois Dermatology Institute
    Chicago, Illinois 60602, United States
  • Dawes Fretzin Clinical Rea Group
    Indianapolis, Indiana 46256, United States
  • Equity Medical LLC
    Bowling Green, Kentucky 42104, United States
  • Dermat. and Adv. Aesthetics
    Lake Charles, Louisiana 70605, United States
  • Michigan Center for Rsrch Company
    Clarkston, Michigan 48346, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202-2689, United States
  • Revival Research Institute
    Troy, Michigan 48084, United States
  • University of Mississippi Med Ctr
    Jackson, Mississippi 39216, United States
  • Care Access Hoboken
    Hoboken, New Jersey 07030, United States
  • Forest Hills Dermatology Group
    New York, New York 10003, United States
  • Icahn School Of Med At Mount Sinai
    New York, New York 10029, United States
  • Skinsearch of Rochester Inc
    Rochester, New York 14623, United States
  • OnSite Clinical Solutions LLC
    Huntersville, North Carolina 28078, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27104, United States
  • Unity Clinical Research
    Oklahoma City, Oklahoma 73118, United States
  • Essential Medical Research
    Tulsa, Oklahoma 74137, United States
  • UP Medical Center H System
    Pittsburgh, Pennsylvania 15213-3403, United States
  • Medical University of South Carolina MUSC
    Charleston, South Carolina 29425, United States
  • Advanced Research Experts
    Nashville, Tennessee 37211, United States
  • Bellaire Dermatology Associates
    Bellaire, Texas 77401, United States
  • RFSA Dermatology
    San Antonio, Texas 78213, United States
  • Virginia Clinical Research
    Norfolk, Virginia 23507, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1119ACN, Argentina
  • Novartis Investigative Site
    CABA, Buenos Aires C1425BEA, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe Province S2000DBS, Argentina
  • Novartis Investigative Site
    CABA, C1428DZF, Argentina
  • Novartis Investigative Site
    Phillip, Australian Capital Territory 2606, Australia
  • Novartis Investigative Site
    Sydney, New South Wales 2010, Australia
  • Novartis Investigative Site
    Westmead, New South Wales 2145, Australia
  • Novartis Investigative Site
    Melbourne, Victoria 3004, Australia
  • Novartis Investigative Site
    Parkville, Victoria 3050, Australia
  • Novartis Investigative Site
    Sofia, Bulgaria 1407, Bulgaria
  • Novartis Investigative Site
    Stara Zagora, Bulgaria 6000, Bulgaria
  • Novartis Investigative Site
    Sofia, 1407, Bulgaria
  • Novartis Investigative Site
    Surrey, British Columbia V3V 0C6, Canada
  • Novartis Investigative Site
    St. John's, Newfoundland and Labrador A1E 1V4, Canada
  • Novartis Investigative Site
    Hamilton, Ontario L8L 3C3, Canada
  • Novartis Investigative Site
    Richmond Hill, Ontario L4C 9M7, Canada
  • Novartis Investigative Site
    Québec, Quebec G1W 4R4, Canada
  • Novartis Investigative Site
    Saint-Jérôme, Quebec J7Z 7E2, Canada
  • Novartis Investigative Site
    Fuzhou, Fujian 350025, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510000, China
  • Novartis Investigative Site
    Wuhan, Hubei 430022, China
  • Novartis Investigative Site
    Changsha, Hunan 410008, China
  • Novartis Investigative Site
    Changchun, Jilin 130021, China
  • Novartis Investigative Site
    Shenyang, Liaoning 110011, China
  • Novartis Investigative Site
    Xian, Shanxi 710004, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Ürümqi, Xinjiang 830001, China
  • Novartis Investigative Site
    Ningbo, Zhejiang 315016, China
  • Novartis Investigative Site
    Beijing, 100144, China
  • Novartis Investigative Site
    Jinan, 250012, China
  • Novartis Investigative Site
    Barranquilla, Atlántico 080002, Colombia
  • Novartis Investigative Site
    Bogota, Cundinamarca 110221, Colombia
  • Novartis Investigative Site
    Cali, Valle del Cauca Department 760032, Colombia
  • Novartis Investigative Site
    Medellín, 050034, Colombia
  • Novartis Investigative Site
    Roskilde, 4000, Denmark
  • Novartis Investigative Site
    Langenau, Baden-Wurttemberg 89129, Germany
  • Novartis Investigative Site
    Darmstadt, Hesse 64283, Germany
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Halle, Saxony-Anhalt 06108, Germany
  • Novartis Investigative Site
    Berlin, 10789, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Bonn, 53105, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Hamburg, 20095, Germany
  • Novartis Investigative Site
    Hanover, 30159, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Münster, 48149, Germany
  • Novartis Investigative Site
    Chaïdári, 124 62, Greece
  • Novartis Investigative Site
    Heraklion Crete., 715 00, Greece
  • Novartis Investigative Site
    Thessaloniki, 546 43, Greece
  • Novartis Investigative Site
    Ancona, AN 60020, Italy
  • Novartis Investigative Site
    Brescia, BS 25123, Italy
  • Novartis Investigative Site
    Catania, CT 95123, Italy
  • Novartis Investigative Site
    Cona, FE 44124, Italy
  • Novartis Investigative Site
    Florence, FI 50122, Italy
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Modena, MO 41124, Italy
  • Novartis Investigative Site
    Pisa, PI 56126, Italy
  • Novartis Investigative Site
    Roma, RM 00168, Italy
  • Novartis Investigative Site
    Torino, TO 10126, Italy
  • Novartis Investigative Site
    Muar town, Johor 84000, Malaysia
  • Novartis Investigative Site
    George Town, Pulau Pinang 10450, Malaysia

Showing the first 100 of 139 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for May 2027, 27 months after the start.

Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's planned 27 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2025
First posted
Jan 29, 2025
StartActual
Jan 31, 2025
Primary completionEst.
May 17, 2027
CompletionEst.
Oct 4, 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06799000
Responsible party
Sponsor
First posted
Jan 29, 2025
Start date
Jan 31, 2025
Primary completion
May 17, 2027 (estimated)
Completion
Oct 4, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion